Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong

Launched by ASTRAZENECA · Apr 30, 2018

Keywords

ClinConnect Summary

This is a multi-center, observational study of patients with locally advanced/metastatic NSCLC who progressed on previous EGFR TKI treatment. Eligible patients will be recruited from participating sites in Hong Kong over a 12 months enrolment period.

Plasma and urine samples will be collected from enrolled patients. Plasma circulating tumor DNA (ctDNA) and urine ctDNA will be analyzed by droplet digital PCR (ddPCR) for detection of T790M mutation and EGFR sensitizing mutations. Patients who are T790M plasma-negative, regardless of the urine testing results, will be recommended to undergo r...

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Provision of written informed consent
• • Locally advanced (stage IIIB) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy
• • Confirmed EGFR sensitizing mutation (exon 19 deletion or exon 21 L858R ) in medical record
• • Progressed on previous EGFR TKI treatment, based on physician judgement, with or without additional lines of treatment
• • Suggested to undergo T790M mutation testing by treating physician, based on physician judgement
• • Exclusion Criteria
• • Had been treated with osimertinib or any other 3rd generation T790M inhibitors
• • Enrollment in studies that prohibit participation in this observational study